Natera, Inc. (NASDAQ:NTRA) Shares Bought by Fulton Bank N.A.

Fulton Bank N.A. grew its position in Natera, Inc. (NASDAQ:NTRA) by 54.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,257 shares of the medical research company’s stock after acquiring an additional 1,508 shares during the quarter. Fulton Bank N.A.’s holdings in Natera were worth $461,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its stake in Natera by 28.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock valued at $45,111,000 after acquiring an additional 159,993 shares during the period. Cerity Partners LLC grew its stake in Natera by 1,043.3% during the 4th quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock worth $5,664,000 after buying an additional 82,514 shares during the last quarter. WCM Investment Management LLC increased its position in Natera by 101.2% in the fourth quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock worth $9,058,000 after buying an additional 73,419 shares during the period. Thematics Asset Management lifted its stake in Natera by 3.1% in the fourth quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock valued at $5,652,000 after buying an additional 2,738 shares during the last quarter. Finally, Crestline Management LP boosted its holdings in shares of Natera by 16.0% during the fourth quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock valued at $4,076,000 after acquiring an additional 8,997 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NTRA. BTIG Research boosted their price objective on Natera from $100.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Robert W. Baird increased their price target on Natera from $99.00 to $117.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. Jefferies Financial Group initiated coverage on shares of Natera in a research note on Monday, June 3rd. They set a “buy” rating and a $142.00 price objective on the stock. TD Cowen upped their price objective on shares of Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Finally, StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $103.27.

Natera Stock Up 0.0 %

Shares of Natera stock traded up $0.03 on Wednesday, hitting $100.95. 508,555 shares of the company traded hands, compared to its average volume of 1,375,504. The company has a quick ratio of 3.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.36. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $117.23. The company has a 50-day moving average price of $107.98 and a 200 day moving average price of $94.51. The company has a market cap of $12.40 billion, a PE ratio of -32.35 and a beta of 1.48.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.16. The firm had revenue of $367.70 million for the quarter, compared to the consensus estimate of $316.31 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The firm’s revenue was up 52.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.23) earnings per share. Sell-side analysts predict that Natera, Inc. will post -2.43 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 1,866 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $99.65, for a total value of $185,946.90. Following the transaction, the chief financial officer now directly owns 71,955 shares in the company, valued at approximately $7,170,315.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Michael Burkes Brophy sold 1,866 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $99.65, for a total transaction of $185,946.90. Following the completion of the transaction, the chief financial officer now directly owns 71,955 shares in the company, valued at $7,170,315.75. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 6,779 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $107.08, for a total transaction of $725,895.32. Following the completion of the sale, the chief executive officer now owns 219,456 shares in the company, valued at approximately $23,499,348.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 118,387 shares of company stock worth $12,684,836. 7.60% of the stock is currently owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.